CMChiara Mazziotta

Chiara Mazziotta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chiara Mazziotta has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hsa-microRNA-34a-5p inhibits virus-negative Merkel cell carcinoma cell proliferation and migration by regulating cell cycle- and EMT-related pathways and suppresses tumor spheroid formation

    by Giada Badiale, Christian Felice Cervellera, Giulia Tonnini, Agnese Pellati, Maria Grazia Romanelli, Andrea Corsi, Angela Valentino, Alberto Righi, Marco Gambarotti, Antoine Touzé, et al.


  • Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment

    by Yekatsiaryna Hushcha, Anna Lisa Giuliani, Martini Fernanda, Ilaria Bononi, Chiara Mazziotta, John Charles Rotondo, Monica De Mattei

    Melasma and other hyperpigmentation disorders represent a significant challenge in dermatology. Tranexamic acid (TXA), traditionally known for its antifibrinolytic activity via inhibition of plasminogen activation, has recently emerged as a promising depigmenting agent. However, its cellular effects on skin cells involved in melanogenesis remain poorly understood. In this study, we investigated TXA's impact on melanocytes, keratinocytes, and inflammatory cells. TXA directly inhibited melanin synthesis in B16 melanoma cells, with an additive effect when combined with α‐arbutin. In keratinocytes and macrophages, TXA attenuated inflammatory responses triggered by the plasminogen/plasmin (Plg/Plm) pathway. Moreover, TXA reduced lipopolysaccharide‐induced pro‐inflammatory gene expression in mouse macrophages, suggesting interference with Toll‐like receptor‐mediated inflammation. These findings highlight TXA's multifaceted actions on skin cells involved in pigmentation and support its therapeutic potential in melasma and potentially other skin diseases.


  • Open Access

    Unraveling the role of flotillin-1 in driving hepatocellular carcinoma progression through transcription factor E3-mediated Golgi stress response

    by Chiara Mazziotta, John Charles Rotondo

    In this editorial, we comment on the article by Zhang et al recently published in the World Journal of Gastroenterology . The manuscript elucidates significant novel mechanisms underlying hepatocellular carcinoma (HCC) progression. HCC is currently considered one of the major causes of global cancer-associated deaths, underscoring the critical need for novel therapeutic targets. Growing evidence underlines the role of the lipid raft protein flotillin-1 (FLOT1) in cancer, whose dysregulation drives tumor cell growth and survival. However, the regulatory role of FLOT1 on Golgi apparatus function in HCC is unknown. In this study, Zhang et al elucidated a pivotal mechanism by which FLOT1 promotes HCC progression through activation of transcription factor E3-mediated Golgi stress response. The study reveals that FLOT1 inhibits the mechanistic target of rapamycin complexes 1 and 2 by ubiquitination, facilitating transcription factor E3 dephosphorylation, nuclear translocation, and subsequent upregulation of Golgi stress-associated genes, thereby leading to enhanced HCC cell growth and invasive capacity. These findings obtained in vitro /in vivo highlight the interplay between FLOT1 and Golgi homeostasis in HCC. Targeting FLOT1 may offer a new strategy for the treatment of HCC.


  • Open Access

    Emerging in vitro models to study Merkel cell carcinoma pathobiology

    by Chiara Mazziotta, John Charles Rotondo

    Merkel cell carcinoma (MCC) is a rare but highly aggressive skin neoplasm, caused in approximately 80% of cases by the genomic integration of Merkel cell polyomavirus (MCPyV) and the expression of the viral small T antigen (sT) and large T antigen (LT) oncoproteins. Virus-negative tumors exhibit extensive UV-induced mutations. Despite such divergent molecular characteristics, the two etiologies share similar morphological and clinical features. The development of novel preclinical in vitro models that effectively recapitulate MCC pathobiology is essential for understanding the mechanisms of MCPyV infection and the cellular ancestry of MCC, a central topic of ongoing investigation and debate. This review provides a comprehensive overview of current two-dimensional (2D) and three-dimensional (3D) in vitro models developed to investigate the molecular and cellular mechanisms of MCC onset and progression. Continuous refinement of cell models that recapitulate MCC pathobiology is essential for advancing our understanding of the mechanisms of tumor onset and progression, thereby enhancing clinical applications for MCC patients.


  • Molecular regulatory mechanisms of Merkel cell differentiation

    by Christian Felice Cervellera, Chiara Mazziotta, Elisa Mazzoni, Ilaria Bononi, Maria Rosa Iaquinta, Mauro Tognon, Fernanda Martini, John Charles Rotondo

    Merkel cells are specialized oval‐shaped epithelial cells located in the basal epidermis and hair follicles, connected with afferent nerve endings responsible for sensory perception of light touch. Recent advances in developmental biology have shed light on the complex regulatory networks governing Merkel cell maturation. The most recent evidence indicates a crosstalk among epigenetic pathways, notably Polycomb multi‐subunit complexes, Merkel cell‐lineage transcription factors such as atonal BHLH transcription factor 1 (ATOH1), SRY‐box transcription factor 2 (SOX2), ISL LIM homeobox 1 (ISL1) and additional players in the regulation of Merkel cell developmental programs. At the same time, the implications of dysregulated Merkel cell‐lineage transcription factors during Merkel cell carcinoma (MCC) onset is under investigation. This review offers a comprehensive overview of the current understanding of the genetic and epigenetic pathways crucial for Merkel cell differentiation. It covers the implication of Merkel cell‐specific developmental programs, the role of epigenetic regulatory Polycomb complexes, and how genetic and epigenetic mechanisms converge to orchestrate Merkel cell differentiation.


  • Open Access

    MALAT1 Expression Is Deregulated in miR-34a Knockout Cell Lines

    by Andrea Corsi, Tonia De Simone, Angela Valentino, Elisa Orlandi, Chiara Stefani, Cristina Patuzzo, Stefania Fochi, Maria Giusy Bruno, Elisabetta Trabetti, John Charles Rotondo, et al.

    Background/Objectives: Non-coding microRNA-34a (miR-34a) regulates the expression of key factors involved in several cellular processes, such as differentiation, apoptosis, proliferation, cell cycle, and senescence. Deregulation of the expression of these factors is implicated in the onset and progression of several human diseases, including cancer, neurodegenerative disorders, and pathologies associated with viral infections and inflammation. Despite numerous studies, the molecular mechanisms regulated by miR-34a remain to be fully understood. The present study aimed to generate miR-34a knockout cell lines to identify novel genes potentially regulated by its expression. Methods: We employed the CRISPR-Cas9 gene editing system to knock out the hsa-miR-34a gene in HeLa and 293T cell lines, two widely used models for studying molecular and cellular mechanisms. We compared proliferation rates and gene expression profiles via RNA-seq and qPCR analyses between the wild-type and miR-34a KO cell lines. Results: Knockout of miR-34a resulted in a decreased proliferation rate in both cell lines. Noteworthy, the ablation of miR-34a resulted in increased expression of the long non-coding RNA MALAT1. Additionally, miR-34a-5p silencing in the A375 melanoma cell line led to MALAT1 overexpression. Conclusions: Our findings support the role of the miR-34a/MALAT1 axis in regulating proliferation processes.


  • Open Access

    The complex conundrum of Merkel cell carcinoma cellular ancestry

    by Chiara Mazziotta, Fernanda Martini, John Charles Rotondo

    Merkel cell carcinoma (MCC) is a rare but lethal skin neoplasm, caused, in approximately 80% of cases, by the genomic integration of Merkel cell polyomavirus (MCPyV) and the expression of viral oncoproteins small T (sT) and large T (LT) antigens. Virus-negative MCCs exhibit extensive UV-induced mutations. Although there is a growing understanding of MCC pathogenesis, the cellular origin of MCC remains a topic of intense investigation and debate. In this perspective, we will provide a description and discussion of the current theories regarding the cellular ancestry of MCC. The most recent findings point in favor of a potential epithelial origin of MCC. MCPyV integration likely occurs in an epithelial precursor cell prior to MCPyV-driven clonal expansion, while the same originating cell type may undergo a specific molecular switch that drives neuroendocrine differentiation, leading to UV-mutated, virus-negative MCCs. Identifying the cellular origin of MCC is crucial for developing accurate pre-clinical models and advancing clinical applications.


  • Increased serum IgG antibody response to Merkel cell polyomavirus oncoproteins in patients with autoimmune rheumatic diseases

    by Chiara Mazziotta, Giulia Tonnini, Milena Oimo, Christian Felice Cervellera, Giada Badiale, Antoine Touzé, Elisa Assirelli, Simona Neri, Francesco Ursini, Maurizio Rossini, et al.

    Autoimmune rheumatic diseases (AIRDs) encompass a spectrum of disorders with a partially understood pathogenesis. A role for polyomaviruses in AIRDs occurrence has been reported. However, the involvement of Merkel cell polyomavirus (MCPyV), the main causative factor of Merkel cell carcinoma (MCC), an aggressive skin neoplasm related to immunosuppression, in AIRDs is unknown. The prevalence/serological profiles of immunoglobulin G (IgG) antibodies to MCPyV large and small T (LT/sT) oncoproteins and viral capsid proteins 1 and 2 (VP1/2) were investigated herein in 540 immunosuppressive treatment-naive AIRD patients, encompassing 447 rheumatoid arthritis (RA) and 93 ankylosing spondylitis (AS) patients by seven MCPyV-specific immunoassays. Control sera from 500 healthy subjects (HS) and 128 MCC patients were included. MCPyV DNA and LT/VP1 mRNAs were evaluated in peripheral blood mononuclear cells (PBMCs) from 75 randomly selected AIRD patients. AIRD patients exhibited higher prevalence and levels (optical densities) of serum anti-oncoprotein IgGs (12%–13%, 0.2–0.6) compared to HS (2%–7%, 0.1–0.4), but lower than MCC patients (70%–83%, 0.2–0.7) (P < .05), with the increase being more pronounced in AS (24%–29%, 0.3–0.8) than in RA (9%–11%, 0.2–0.8) (P < .05). Conversely, similar rates and levels of serum anti-capsid proteins IgGs were determined in most cases between study and control groups (60%–73%, 0.1–0.3) (P > .05). Moreover, receiver operating characteristic (ROC) curves indicated that the MCPyV serology can discriminate AIRD patients from HS (P < .0001). A fraction (11%) of AIRD PBMCs tested MCPyV DNA (7.4 ± 2.6 [copy/104 cells]) and mRNA-positive (0.5–0.1 [1/ΔCt]), while matched sera showed high rates and levels of anti-oncoproteins IgGs (38%–75%, 0.2–2). Our study provides the first evidence that AIRD patients are immunologically responsive to MCPyV oncoproteins, with a fraction of these patients presenting an increased presentation of MCPyV LT and sT antigens, possibly due to viral LT/sT oncogene expression in their PBMCs. These data suggest an association between MCPyV infection and AIRDs pathogenesis.


  • Open Access

    Serum antibodies against mimotopes of Merkel cell polyomavirus oncoproteins detected by a novel immunoassay in healthy individuals and Merkel cell carcinoma patients

    by Chiara Mazziotta, Giada Badiale, Christian Felice Cervellera, Giulia Tonnini, Milena Oimo, Antoine Touzé, Françoise Arnold, Stefania Zanussi, Ornella Schioppa, Giuseppe Fanetti, et al.

    Merkel cell polyomavirus (MCPyV) is the foremost causative factor of Merkel cell carcinoma (MCC), a rare yet highly aggressive skin cancer. Although the evaluation of circulating IgG antibodies against Merkel cell polyomavirus (MCPyV) LT/sT oncoproteins is clinically useful for MCC diagnosis/prognosis, a limited number of assays for identifying such antibodies have been developed. Herein, a novel indirect immunoassay with synthetic epitopes/mimotopes of MCPyV oncoproteins was computationally designed and experimentally validated on control sera and sera from healthy individuals and MCC patients. Upon computational design of five synthetic peptides, the performance of the immunoassay in detecting anti‐oncoprotein IgGs in MCPyV‐positive and ‐negative control sera was evaluated. The immunoassay was afterwards extended on sera from healthy individuals, and, for longitudinal analysis, MCC patients. Performance properties such as sensitivity and specificity and positive/negative predictive values were adequate. Receiver‐operating characteristic (ROC) curves indicated that the areas under the curves (AUCs) were within the low/moderately accurate ranges. Immunoassay was repeatable, reproducible and accurate. As expected, the serum anti‐oncoprotein IgG prevalence in healthy individuals was low (2%–5%). Anti‐oncoprotein IgGs slightly increased when MCC patients experienced partial tumour remission and/or stable disease, compared to baseline. Our data indicate that the newly developed immunoassay is reliable for detecting circulating anti‐oncoprotein IgGs both in healthy individuals and MCC patients.


  • Open Access

    Distinct retinoic gene signatures discriminate Merkel cell polyomavirus‐positive from ‐negative Merkel cell carcinoma cells

    by Chiara Mazziotta, Christian Felice Cervellera, Giada Badiale, Ilaria Vitali, Antoine Touzé, Mauro Tognon, Fernanda Martini, John Charles Rotondo

    Limited molecular knowledge of Merkel cell polyomavirus (MCPyV)‐positive and ‐negative Merkel cell carcinoma (MCC) subsets (MCCP/MCCN) has prevented so far the identification of the MCC origin cell type and, therefore, the development of effective therapies. The retinoic gene signature was investigated in various MCCP, MCCN, and control fibroblast/epithelial cell lines to elucidate the heterogeneous nature of MCC. Hierarchical clustering and principal component analysis indicated that MCCP and MCCN cells were clusterizable from each other and control cells, according to their retinoic gene signature. MCCP versus MCCN differentially expressed genes (n = 43) were identified. Protein–protein interaction network indicated SOX2, ISL1, PAX6, FGF8, ASCL1, OLIG2, SHH, and GLI1 as upregulated hub genes and JAG1 and MYC as downregulated hub genes in MCCP compared to MCCN. Numerous MCCP‐associated hub genes were DNA‐binding/‐transcription factors involved in neurological and Merkel cell development and stemness. Enrichment analyses indicated that MCCP versus MCCN differentially expressed genes predominantly encode for to DNA‐binding/‐transcription factors involved in development, stemness, invasiveness, and cancer. Our findings suggest the neuroendocrine origin of MCCP, by which neuronal precursor cells could undergo an MCPyV‐driven transformation. These overarching results might open the way to novel retinoid‐based MCC therapies.